Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy

Introduction: The addition of durvalumab after chemoradiation therapy (CRT) in unresectable stage III NSCLC significantly improves survival. The benefit of this approach in elderly patients is controversial given the toxicity associated with CRT and, thus, may be underutilized. We sought to investig...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Sally C.M. Lau, MD, MPH, Malcolm Ryan, BSc, Jessica Weiss, PhD, Aline Fusco Fares, MD, Miguel Garcia, MD, Sabine Schmid, MD, Shelley Kuang, MD, Deirdre Kelly, MB BCh BAO, Ming Sound Tsao, MD, Penelope A. Bradbury, MB BCh, Byoung Chun J. Cho, MD, Alexander Sun, MD, Srinivas Raman, MD, Andrew Hope, MD, Meredith Giuliani, MBBS, MEd, PhD, Benjamin H. Lok, MD, PhD, Andrea Bezjak, MD, Geoffrey Liu, MD, MSc, Natasha B. Leighl, MD, MSc, Frances A. Shepherd, MD, Adrian G. Sacher, MD, MMSc
Format:	Article
Language:	English
Published:	Elsevier 2021-12-01
Subjects:	Elderly Chemoradiotherapy Immune checkpoint inhibitors Multimodality treatment Safety
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364321001107